Company Overview of Conatus Pharmaceuticals Inc.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.
16745 West Bernardo Drive
San Diego, CA 92121
Founded in 2005
Key Executives for Conatus Pharmaceuticals Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $460.0K
Co-Founder, Chief Scientific Officer and Executive Vice President of Research & Development
Total Annual Compensation: $325.6K
Executive Vice President of Clinical Development
Total Annual Compensation: $94.0K
Compensation as of Fiscal Year 2014.
Conatus Pharmaceuticals Inc. Key Developments
Conatus Pharmaceuticals Inc. - Special Call
Sep 23 15
To discuss the top-line results and provide a mechanism-focused overview of liver cirrhosis and portal hypertension
Conatus Pharmaceuticals Inc. Announces Top-Line Results from Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients with Liver Cirrhosis
Sep 23 15
Conatus Pharmaceuticals Inc. announced that the company's exploratory Phase 2 Portal Hypertension (PH) clinical trial of emricasan, a first-in-class, orally active pan-caspase inhibitor, met the following primary endpoints: a clinically meaningful and statistically significant change from baseline in hepatic venous pressure gradient (HVPG), a measurement of pressure in the portal vein, in patients with liver cirrhosis and severe portal hypertension (HVPG =12 mmHg); and a statistically significant change from baseline in cleaved Cytokeratin 18 (cCK18), a mechanism-specific biomarker of excessive cell death that contributes to chronic inflammation, in the total evaluable liver cirrhosis patient population. The open-label PH trial was conducted at nine U.S. sites and enrolled 23 patients (22 evaluable) with portal hypertension and compensated liver cirrhosis that was predominantly due to nonalcoholic steatohepatitis (NASH) or hepatitis C virus (HCV), including patients with active HCV infection and patients who had a sustained viral response (SVR) to antiviral therapy. Portal hypertension, or elevated blood pressure in the major vein feeding into the liver, was confirmed by HVPG measurement >5 mmHg at baseline and measured again after treatment with 25 mg of emricasan orally twice daily for 28 days. Patients were divided according to the HVPG therapeutic threshold of 12 mmHg, which indicates more severe portal hypertension. Reducing the HVPG to below 12 mmHg or reducing HVPG by =10% or =20% has been strongly associated with clinical benefit in this patient population. The HVPG endpoint was analyzed in: patients with baseline HVPG values =12 mmHg (N=12); patients with baseline HVPG values <12 mmHg (N=10); and all evaluable patients (N=22). HVPG measurement was standardized, and tracings were evaluated by a single expert reader not otherwise involved in the PH trial. HVPG decreased by a mean of 3.7 mmHg from the mean baseline of 20.6 mmHg in the higher baseline HVPG group (p<0.003), with 8 of 12 achieving a =10% decrease, 4 of 12 achieving a =20% decrease, and 2 of 12 achieving reductions below 12 mmHg. The changes from baseline HVPG were not statistically significant in the lower baseline HVPG group (+1.9 mmHg mean increase from mean baseline of 8.1 mmHg; p=0.12) or the total evaluable patient population (–1.1 mmHg from mean baseline of 15.2 mmHg; p=0.26). The cCK18 endpoint, analyzed in the total evaluable patient population, showed a statistically significant reduction (p<0.03) from baseline. Consistent with results from prior trials, emricasan was safe and well tolerated in the PH trial, with no dose-limiting toxicities and no drug-related serious adverse events. Detailed results are expected to be presented in a future scientific forum.
Conatus Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 5 15
Conatus Pharmaceuticals Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported interest income was $17,977 against $15,343 a year ago. Net loss was $6,057,254 against $5,303,024 a year ago. Net loss per share, basic and diluted was $0.31 against $0.34 a year ago.
For the six months, the company reported interest income was $29,396 against $36,116 a year ago. Net loss was $12,036,918 against $10,546,380 a year ago. Net loss per share, basic and diluted was $0.69 against $0.68 a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|